RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Sinovac Biotech of Beijing reported its Sabin strain inactivated polio vaccine (sIPV) proved non-inferiority in China Phase III trials. Because the Sinovac vaccine does not contain any live virus, it is considered safer than its competition, oral polio vaccine (OPV) and inactivated polio vaccine (IPV). Two months ago, Sinovac instituted a poison pill plan against a group of investors with a 40% stake in the company. In 2018, outsiders contested Sinovac’s management-led slate of directors. Both sides claimed victory, with the outcome being fought in suits and counter-suits, which continue.
Source: China Biotoday
